Lianbio (LIAN)

They are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. They have purposefully designed their organization to successfully execute on their vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. They are establishing an international infrastructure to position ourselves as a partner of choice with a platform to provide access to their target markets. Their model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches that they believe will enable them to deliver innovative therapeutic solutions to patients in Greater China, including Mainland China, Hong Kong, Taiwan and Macau, and other Asian markets. Their deep relationships with their founder, Perceptive Advisors (“Perceptive”), as well as their broader investor base, position them to access and capture attractive business development opportunities. They have also entered into high-value strategic collaborations with Pfizer Inc. (“Pfizer”), which offers optionality to leverage its broad reach and commercial infrastructure in Greater China, and BridgeBio Pharma LLC (“BridgeBio”), which provides preferential access to an innovative pipeline of more than 20 product candidates in development.

What do you think will happen with the GLSI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)